MHRA omeprazole
This article was originally published in The Tan Sheet
Executive Summary
UK medicines agency seeks comments by June 27 on reclassification of Gastro-resistant Tablets (omeprazole 10 mg) from "prescription only medicine" to "pharmacy status," according to May 16 1MHRA consultation document. Galpharm Healthcare's reclassification proposal "restricts omeprazole sale to 10 mg x 28 tablets (14-28 days treatment) and advises against long-term use without reference to the pharmacist," agency notes. Proposed P status "and pack size will also limit the indirect danger posed by the masking of serious underlying disease, which is in line with the approved dosage regimens for nonprescription omeprazole in Sweden and the USA," MHRA states. FDA has deemed AstraZeneca/P&G's Prilosec approvable for OTC use pending label revisions (2"The Tan Sheet" Aug. 26, 2002, In Brief)...
You may also be interested in...
Prilosec 1 “approvable”
P&G expects final approval of OTC Prilosec (omeprazole) for prevention of frequent heartburn early in the first quarter of 2003, firm says following Aug. 8 FDA letter deeming drug "approvable" pending label modifications and a label comprehension study. Company says FDA's correspondence gives it a "much better understanding of what is needed in a label comprehension study." In June, agency advisory committee members voted 16-2 in favor of switching the proton pump inhibitor OTC, but recommended significant labeling changes and an additional comprehension study (1"The Tan Sheet" June 24, 2002, p. 3). FDA's letter came three days after P&G told analysts during its Aug. 5 fiscal year-end earnings call that it hoped for final OTC approval before 2003 (2"The Tan Sheet" Aug. 12, 2002, p. 7)...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.